Analysts predict that NeuroMetrix, Inc. (NASDAQ:NURO) will post earnings of ($1.60) per share for the current quarter, according to Zacks. Zero analysts have made estimates for NeuroMetrix’s earnings. NeuroMetrix reported earnings per share of ($6.08) during the same quarter last year, which suggests a positive year over year growth rate of 73.7%. The company is expected to issue its next quarterly earnings report before the market opens on Thursday, October 19th.

On average, analysts expect that NeuroMetrix will report full-year earnings of ($10.29) per share for the current year. For the next financial year, analysts expect that the company will post earnings of ($2.73) per share, with EPS estimates ranging from ($4.50) to ($0.95). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover NeuroMetrix.

NURO has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded NeuroMetrix from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. HC Wainwright restated a “buy” rating and issued a $3.00 price objective (down previously from $10.00) on shares of NeuroMetrix in a research note on Friday, October 20th.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at

Shares of NeuroMetrix (NURO) opened at 1.779 on Friday. The firm’s market cap is $3.31 million. NeuroMetrix has a one year low of $0.38 and a one year high of $4.50. The firm’s 50-day moving average price is $1.97 and its 200 day moving average price is $2.11.

About NeuroMetrix

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Get a free copy of the Zacks research report on NeuroMetrix (NURO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with's FREE daily email newsletter.